OncLive TV

Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology

August 1st 2016

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses how the use of PD-1/PD-L1 inhibitors in multiple tumor types has dramatically evolved over the last 4 years.

Dr. Holmes Discusses Late Recurrence and the MA.17R Trial in Breast Cancer

July 30th 2016

Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

July 29th 2016

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Dr. Falchook on KTN3379 in Advanced Tumors

July 29th 2016

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ErbB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

Dr. El-Jawahri on Early Integrated Palliative Care in Patients With Lung or GI Cancer

July 29th 2016

Areej R. El-Jawahri, MD, assistant in Medicine, Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses a study examining early integrated palliative care for patients with gastrointestinal (GI) or lung cancer and the impact it has on family caregiver outcomes.

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

July 29th 2016

Dr. Raoul Tibes Discusses FLT3 Inhibitors in AML

July 29th 2016

Impact of Precision Medicine in Refractory Malignancies

July 28th 2016

Maria Schwaederle, PharmD, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, discusses results of a meta-analysis of 13,203 patients in phase I clinical trials.

Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28th 2016

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.

Dr. Angela DeMichele on Selecting Best Therapies in TNBC

July 28th 2016

Dr. Max Topp on the TOWER study and Blinatumomab in ALL

July 28th 2016

Dr. Kaufman on Avelumab in Merkel Cell Carcinoma

July 28th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

Dr. Sparano on the Role of Endocrine Therapy in Breast Cancer

July 27th 2016

Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer.

Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

July 27th 2016

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

July 27th 2016

Dr. van den Bent on Adjuvant Temozolomide in Anaplastic Glioma

July 27th 2016

Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

July 26th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016